Second of 2 parts featuring an interview with Stephen Strickland, MD, MSCI,director, Leukemia Research for Sarah Cannon ...

First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research ...

A novel off-the-shelf CAR NK therapy using logic gates has shown complete remissions in relapsed AML patients, according to ...

Researchers will use Cellply's VivaCyte platform to conduct single-cell analyses of NK cells and evaluate their ability to treat the bone marrow cancer.

Lipid receptor SR-B1 identified as a potential immunotherapy target to boost NK cell antitumor response in advanced ovarian ...

General and administrative (G&A) expenses were $12.4 million for the first quarter of 2025, which included $5.1 million of restructuring expenses in March 2025. Non-cash stock-based compensation ...

A Ludwig Cancer Research study has identified a key mechanism by which advanced ovarian cancers suppress anti-tumor immune responses and resist immunotherapies.

GI Innovation, a South Korean biotech company, announced on May 13 that it has been selected as a semi-finalist in the XPRIZE ...

SENTI-202 is a first-in-class off-the-shelf CAR-NK cell therapy targeting CD33 and FLT3 for treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML).

A global study suggests that using small molecule inhibitors followed by epigenetic modifiers may significantly improve ...

Senti Biosciences, Inc.’s SNTI share price has dipped by 6.26%, which has investors questioning if this is right time to buy.